These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 30303650

  • 1. [EVALUATION OF CARDIOVASCULAR RISKS WITH THE USE OF MORPHOGENETIC KLOTHO PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASE].
    Mukhin NA, Milovanova LY, Fomin VV, Kozlovskaya LV, Taranova MV, Androsova TV, Borisov AA.
    Klin Med (Mosk); 2017; 95(3):272-7. PubMed ID: 30303650
    [Abstract] [Full Text] [Related]

  • 2. [Decreased Serum Levels of Klotho Protein in Chronic Kidney Disease Patients: Clinical Imortance].
    Milovanova LY, Mukhin NA, Kozlovskaya LV, Milovanov YS, Kiyakbaev GG, Rogova IV, Lebedeva MV, Androsova TV, Milovanova SY, Gil AY, Taranova MV.
    Vestn Ross Akad Med Nauk; 2016; 71(4):288-96. PubMed ID: 29297646
    [Abstract] [Full Text] [Related]

  • 3. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY, Milovanov YS, Kudryavtseva DV, Markina MM, Milovanova SY, Kozlovskaya LV, Lebedeva MV, Beketov VD, Moiseev SV, Mukhin NA, Fomin VV, Svistunov AA.
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [Abstract] [Full Text] [Related]

  • 4. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
    Milovanova LY, Kozlovskaya LV, Markina MM, Milovanova SY, Borisov AA, Mukhin NA, Fomin VV, Moiseev SV.
    Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
    [Abstract] [Full Text] [Related]

  • 5. [New markers of cardio-renal links in chronic kidney disease].
    Milovanova LIu, Milovanov IuS, Kozlovskaia LV, Mukhin NA.
    Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
    [Abstract] [Full Text] [Related]

  • 6. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
    Milovanov YS, Mukhin NA, Kozlovskaya LV, Milovanova SY, Markina MM.
    Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
    [Abstract] [Full Text] [Related]

  • 7. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
    Milovanova LIu, Milovanov IuS, Kozlovskaia LV, Mukhin NA.
    Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
    [Abstract] [Full Text] [Related]

  • 8. The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study.
    Kim HJ, Kang E, Oh YK, Kim YH, Han SH, Yoo TH, Chae DW, Lee J, Ahn C, Oh KH.
    BMC Nephrol; 2018 Mar 05; 19(1):51. PubMed ID: 29506503
    [Abstract] [Full Text] [Related]

  • 9. Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations.
    Adema AY, van Ittersum FJ, Hoenderop JG, de Borst MH, Nanayakkara PW, Ter Wee PM, Heijboer AC, Vervloet MG, NIGRAM consortium.
    PLoS One; 2016 Mar 05; 11(1):e0144121. PubMed ID: 26807718
    [Abstract] [Full Text] [Related]

  • 10. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL.
    Nephrol Dial Transplant; 2013 Feb 05; 28(2):352-9. PubMed ID: 23129826
    [Abstract] [Full Text] [Related]

  • 11. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.
    Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, Inoue M, Fujimoto S, Ikebe M, Yuasa K, Yamanaka S, Sugiura T, Terada Y.
    Clin Exp Nephrol; 2012 Oct 05; 16(5):722-9. PubMed ID: 22457086
    [Abstract] [Full Text] [Related]

  • 12. Circulating α-klotho levels in CKD and relationship to progression.
    Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, Shin DH, Doh FM, Koo HM, Ko KI, Kim CH, Oh HJ, Yoo TH, Kang SW, Han DS, Han SH.
    Am J Kidney Dis; 2013 Jun 05; 61(6):899-909. PubMed ID: 23540260
    [Abstract] [Full Text] [Related]

  • 13. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease.
    Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue K, Ogawa A, Yamanari T, Kikumoto Y, Uchida HA, Kitamura S, Maeshima Y, Nakamura K, Ito H, Makino H.
    PLoS One; 2013 Jun 05; 8(2):e56695. PubMed ID: 23431388
    [Abstract] [Full Text] [Related]

  • 14. [Low serum Klotho level as a predictor of calcification of the heart and blood vessels in patients with CKD stages 2-5D].
    Milovanova LY, Lysenko Kozlovskaya LV, Milovanova SY, Taranova MV, Kozlov VV, Reshetnikov VA, Lebedeva MV, Androsova TV, Zubacheva DO, Chebotareva NV.
    Ter Arkh; 2020 Jul 09; 92(6):37-45. PubMed ID: 33346491
    [Abstract] [Full Text] [Related]

  • 15. Plasma s-Klotho is related to kidney function and predicts adverse renal outcomes in patients with advanced chronic kidney disease.
    Liu QF, Ye JM, Yu LX, He AL, Sun Q, He DW, Li SS.
    J Investig Med; 2018 Mar 09; 66(3):669-675. PubMed ID: 29061648
    [Abstract] [Full Text] [Related]

  • 16. Serum level of soluble (pro)renin receptor is modulated in chronic kidney disease.
    Hamada K, Taniguchi Y, Shimamura Y, Inoue K, Ogata K, Ishihara M, Horino T, Fujimoto S, Ohguro T, Yoshimoto Y, Ikebe M, Yuasa K, Hoshino E, Iiyama T, Ichihara A, Terada Y.
    Clin Exp Nephrol; 2013 Dec 09; 17(6):848-56. PubMed ID: 23564382
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of fibroblast growth factor-23 and soluble alpha klotho in different stages of chronic kidney disease.
    Khodeir SA, Okda HI, Abdalal HM.
    Saudi J Kidney Dis Transpl; 2019 Dec 09; 30(1):108-118. PubMed ID: 30804272
    [Abstract] [Full Text] [Related]

  • 18. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y, Olauson H, Vavilis G, Hammar U, Herthelius M, Axelsson J, Bárány P.
    Pediatr Nephrol; 2018 Jan 09; 33(1):147-157. PubMed ID: 28795324
    [Abstract] [Full Text] [Related]

  • 19. [Effects of keto/amino acids and a low-protein diet on the nutritional status of patients with Stages 3B-4 chronic kidney disease].
    Milovanova SY, Milovanov YS, Taranova MV, Dobrosmyslov IA.
    Ter Arkh; 2017 Jan 09; 89(6):30-33. PubMed ID: 28745686
    [Abstract] [Full Text] [Related]

  • 20. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
    Huang RS, Cheng YM, Zeng XX, Kim S, Fu P.
    Chin Med J (Engl); 2016 Mar 05; 129(5):562-9. PubMed ID: 26904991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.